Login / Signup

Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.

Andrew T KuykendallQianxing MoDavid A SallmanNajla Al AliOnyee ChanSeongseok YunKendra L SweetEric PadronJeffrey E LancetRami S Komrokji
Published in: Cancer (2022)
A significant minority of patients with myelofibrosis (MF) present with low platelets. Historically, these patients have been viewed as having "high-risk" disease, but this may not be uniformly true. Our study shows that there are various different causes for low platelets in MF, some of which represent high-risk disease whereas others do not. Additionally, our study shows that genetic mutations affecting the genes SRSF2 and TP53 are uniquely problematic in this group, as is a low serum albumin level. This study helps to risk-stratify MF patients with thrombocytopenia, thereby providing more information to guide informed and individualized treatment decisions.
Keyphrases
  • genome wide
  • end stage renal disease
  • chronic kidney disease
  • healthcare
  • newly diagnosed
  • gene expression
  • patient reported